GOPC:ROS1 and other ROS1 fusions represent a rare but recurrent drug target in a variety of glioma types. Sievers P, Stichel D, Sill M, Schrimpf D, et al. Acta Neuropathol 2021 Sep 18. pii: 10.1007/s00401-021-02369.

Read + Share

Amedeo Smart

Independent Medical Education

Sievers P, Stichel D, Sill M, Schrimpf D, et al. GOPC:ROS1 and other ROS1 fusions represent a rare but recurrent drug target in a variety of glioma types. Acta Neuropathol 2021 Sep 18. pii: 10.1007/s00401-021-02369.
PMID: 34536122